dapi staining (Beyotime)
Beyotime is a verified supplier 
Beyotime manufactures this product 
99
Structured Review
Beyotime
dapi staining
Dapi Staining, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 32584 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+staining/DAPI/pmc13616917-395-20-22
Average 99 stars, based on 32584 article reviews
Dapi Staining, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 32584 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+staining/DAPI/pmc13616917-395-20-22
Average 99 stars, based on 32584 article reviews
dapi staining - by Bioz Stars,
2026-10
99/100 stars
Images
1) Product Images from "Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation"
Article Title: Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation
Journal: Signal Transduction and Targeted Therapy
doi: 10.1038/s41392-026-02875-2
Figure Legend Snippet: TKTL1 drives tumor progression while potentiating anti-PD-1 immunotherapy sensitivity rather than apatinib in HCC. a Schematic of the orthotopic tumor mouse model: Hepa1-6 cells transduced with OE-TKTL1 (TKTL1 overexpression) or OE-VE (vector control) lentiviruses were subcutaneously implanted, followed by tumor transplantation to the liver. Anti-PD-1 treatment was administered, with live imaging at day 21 and sample harvest at day 42. b Tumor growth curves of orthotopic models in OE-VE, OE-TKTL1, OE-VE+Anti-PD-1, and OE-TKTL1+Anti-PD-1 groups (days 21, 28, 35). c Quantification of tumor volume and tumor weight in each treatment group. Data are mean ± SD ( n = 5, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). d TUNEL immunofluorescence staining of orthotopic tumors to detect apoptotic cells. Scale bar: 50 µm. e Ki67 immunofluorescence staining of orthotopic tumors to assess cell proliferation. Scale bar: 50 µm. f Quantification of TUNEL-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, *** p < 0.001, **** p < 0.0001; One-way ANOVA). g Quantification of Ki67-positive cells in orthotopic tumors. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). h Immunofluorescence staining and analysis of CD8 + (green) and PD-1 + (red) T cells in orthotopic tumors. Nuclei: DAPI (blue). Scale bar: 50 µm. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). i Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in orthotopic tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). j Schematic of the diethylnitrosamine (DEN)/carbon tetrachloride (CCl4)-induced orthotopic HCC model: Mice were treated with DEN+CCl4, followed by AAV-VE (vector control) or AAV-TKTL1 injection at week 20, anti-PD-1 treatment from week 24, MRI scanning, and liver tissue harvest at week 28. k Representative micro-MRI images of mouse livers pre- and post-treatment; representative photographs of excised livers. Scale bar: 1 cm. H&E staining of tumor (T) and peritumoral (P) tissues from DEN/CCl4-induced models. Scale bar: 50 µm. l TUNEL and Ki67 immunofluorescence staining of DEN/CCl4-induced tumor tissues. Scale bar: 50 µm. m Quantification of tumor size changes pre- and post-treatment in DEN/CCl4-induced models related to ( k ). Data are mean ± SD ( n = 5, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). n Quantification of TUNEL-positive and Ki67-positive cells in DEN/CCl4-induced models related to ( l ). Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, *** p < 0.001, **** p < 0.0001; One-way ANOVA). o Immunofluorescence staining of CD8 + and PD-1 + CD8 + T cells in DEN/CCl4-induced tumors. Scale bar: 50 µm. p Quantification of CD8 + and PD-1 + CD8 + T cell proportions in DEN/CCl4-induced tumors. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001; One-way ANOVA). q Flow cytometry analysis of CD8 + T cell exhaustion markers (PD-1, CTLA-4, TOX) and effector cytokine (IFN-γ) in DEN/CCl4-induced tumor tissues. Data are mean ± SD ( n = 3, ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; One-way ANOVA). r Schematic illustrating the role of TKTL1 in promoting HCC progression and sensitizing tumors to anti-PD-1 immunotherapy via modulating CD8 + T cell function in the TME
Techniques Used: Sensitivity, Transduction, Over Expression, Plasmid Preparation, Control, Transplantation Assay, Imaging, TUNEL Assay, Immunofluorescence, Staining, Analysis, Flow Cytometry, Injection, Tissue, Micro-MRI, Cell Function Assay
Figure Legend Snippet: TKTL1 reprograms glucose metabolism through glycolysis instead of the PPP to stabilize the HIF-1α/HK2/PD-L1 axis and drive anti-PD-1 sensitivity in HCC. a mRNA expression of glycolysis-related genes (SLC2A1, HK2, HKDC1) in TKTL1-knockdown Hep-3B cells, determined by RNA sequencing. b KEGG pathway enrichment analysis of downregulated differentially expressed genes (DEGs) in TKTL1-knockdown Hep-3B cells, highlighting Glycolysis/Gluconeogenesis and HIF-1α signaling pathways. c Bubble plot of KEGG pathway enrichment for downregulated metabolites from non-targeted metabolomics of TKTL1-knockdown cells, focusing on central carbon metabolism. d Integrative analysis of downregulated DEGs (RNA sequencing) and metabolites (non-targeted metabolomics), visualized as a ranked plot showing enrichment in glycolytic pathways. e Western blot analysis of glycolytic enzymes (GLUT1, HK2, PKM2, ENO1, LDHA) and TKTL1 in HCC-LM3 and Hep-3B cells with TKTL1 knockdown or overexpression. β-actin serves as a loading control. f 13 C-labeled glucose metabolic flux tracing analysis, showing the relative abundance of metabolites in glycolysis, PPP and tricarboxylic acid (TCA) cycle in TKTL1-knockdown vs. negative control (NC) cells. g Extracellular acidification rate (ECAR) measurements (left) and lactic acid production (right) in HCC-LM3 and Hep-3B cells under TKTL1 knockdown or overexpression. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; Student’s t-test). h , i Western blot analysis of TKTL1, HIF-1α, HK2, and PD-L1 protein expression in HCC-LM3 and Hep-3B cells with TKTL1 knockdown or overexpression. β-actin serves as a loading control. Data are mean ± SD ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; Student’s t-test). j Immunofluorescence staining of TKTL1, HIF-1α, and HK2 protein expression in HCC tissues. Nuclei: DAPI (blue). Scale bar: 150 µm
Techniques Used: Sensitivity, Expressing, Knockdown, RNA Sequencing, Analysis, Protein-Protein interactions, Western Blot, Over Expression, Control, Labeling, Negative Control, Immunofluorescence, Staining
Figure Legend Snippet: TKTL1 activates glycolysis pathway by promoting HIF-1α deubiquitination through recruitment of USP9X in HCC. a Cycloheximide (CHX) chase assay in OE-VE (vector control) and OE-TKTL1 (TKTL1 overexpression) cells, assessing HIF-1α protein degradation kinetics over 0, 4, 8, and 12 h. β-actin serves as a loading control. b CHX chase assay in Sh-NC (negative control) and Sh-TKTL1 (TKTL1 knockdown) cells, evaluating HIF-1α degradation with or without proteasome inhibitor MG132 treatment. β-actin serves as a loading control. c Ubiquitination assay of HIF-1α in HCC-LM3 (Sh-NC vs. Sh-TKTL1) and Hep-3B (OE-VE vs. OE-TKTL1) cells treated with MG132. Immunoprecipitation (IP) with HIF-1α antibody and antibody incubation with ubiquitin (Ub) antibody detect ubiquitinated HIF-1α. d Co-immunoprecipitation (Co-IP) assay of endogenous proteins in HCC-LM3 and Hep-3B cells, confirming the interaction between TKTL1 and HIF-1α. IgG serves as a negative control; input lysates verify protein expression. e Co-IP assay of exogenous proteins in HEK-293T cells transfected with TKTL1 and HIF-1α expression plasmids, validating the TKTL1-HIF-1α interaction. IgG serves as a negative control. f Intersection analysis of TKTL1-interacting proteins identified via IP and deubiquitinating enzyme (DUB) family members, pinpointing USP9X as a key overlapping binding partner of TKTL1. g , h Co-IP assay identifying USP9X as a TKTL1-interacting protein. Co-IP assay demonstrating the interaction between USP9X and HIF-1α. IgG serves as a negative control. i GST-pull down assay transfected with Myc-USP9X, HA-TKTL1, and Flag-HIF-1α plasmids, verifying the formation of the TKTL1-USP9X-HIF-1α ternary complex. j AI-predicted structural model of the TKTL1-USP9X-HIF-1α ternary complex, illustrating the binding interface and spatial configuration of the three proteins. k IP assay using HIF-1α domain mutants in HEK-293T cells, confirming that USP9X binds to the inhibitory domain (ID) of HIF-1α. l IP assay using TKTL1 domain mutants in HEK-293T cells, identifying that HIF-1α binds to the T-pyr domain of TKTL1 and USP9X binds to the T-pyr domain of TKTL1. m Confocal laser scanning microscopy showing the cytoplasmic colocalization of TKTL1, HIF-1α, and USP9X in HCC-LM3 and Hep-3B cells. Nuclei are stained with DAPI (blue). n Immunofluorescence staining of HCC tissue microarrays showing the colocalization of TKTL1, HIF-1α, and USP9X. Inserted merge images confirm triprotein colocalization. Correlation analysis of TKTL1 and HIF-1α expression levels in HCC tissues (Pearson’s correlation coefficient: r = 0.1107, p = 0.003). Scale bar: 150 µm
Techniques Used: Plasmid Preparation, Control, Over Expression, Negative Control, Knockdown, Ubiquitin Proteomics, Immunoprecipitation, Incubation, Co-Immunoprecipitation Assay, Expressing, Transfection, Analysis, Binding Assay, GST Pulldown Assay, Confocal, Laser-Scanning Microscopy, Staining, Immunofluorescence, Tissue
Related Articles
Staining:Article Title: Chemo-metallo nanodrivers for spatiotemporally controlled in situ vaccination Article Snippet: .. Cell staining and viability assays were performed using a LIVE/DEAD kit (calcein AM/propidium iodide), an annexin V–FITC/PI apoptosis detection kit, MTT reagent, Alexa Fluor 488–conjugated secondary antibody, and Article Title: CD52+ cells are associated with faster short-term neutrophil recovery in mobilized hematopoietic stem cell transplant. Article Snippet: .. Cells were stained with CD52 primary antibody (Bioss, #bs-34117R) at 4 oC for overnight, and subsequently incubated for 2 hours at 37 oC with the Alexa Flur 488- conjugated anti-rabbit secondary antibody (Invitrogen, #A21206) and Article Title: DEAD-box RNA helicase 21 interacts with the nucleocapsid protein and inhibits porcine deltacoronavirus infection through upregulation of interferon responses. Article Snippet: The cells were then incubated with primary antibodies for 1 h, followed by washing with PBS and incubation with Alexa Fluor 488- and 594-conjugated secondary antibodies (Thermo Fisher Scientific) for 1 h at 37°C in the dark. .. Afterward, the cells were stained with MTT Assay:Article Title: Chemo-metallo nanodrivers for spatiotemporally controlled in situ vaccination Article Snippet: .. Cell staining and viability assays were performed using a LIVE/DEAD kit (calcein AM/propidium iodide), an annexin V–FITC/PI apoptosis detection kit, MTT reagent, Alexa Fluor 488–conjugated secondary antibody, and Incubation:Article Title: CD52+ cells are associated with faster short-term neutrophil recovery in mobilized hematopoietic stem cell transplant. Article Snippet: .. Cells were stained with CD52 primary antibody (Bioss, #bs-34117R) at 4 oC for overnight, and subsequently incubated for 2 hours at 37 oC with the Alexa Flur 488- conjugated anti-rabbit secondary antibody (Invitrogen, #A21206) and Article Title: Glucocorticoid-induced METTL3 promotes SONFH by enhancing MEG3 m6A methylation and subsequent ABL2 upregulation. Article Snippet: Background: Steroid-induced osteonecrosis of the femoral head (SONFH) is a refractory orthopedic disease.. While N6-methyladenosine (m6A) modification is implicated in bone metabolism, its specific role and mechanism in SONFH pathogenesis require further elucidation.. Methods: Bioinformatics analysis identified key m6A-related genes. TUNEL Assay:Article Title: Glucocorticoid-induced METTL3 promotes SONFH by enhancing MEG3 m6A methylation and subsequent ABL2 upregulation. Article Snippet: Background: Steroid-induced osteonecrosis of the femoral head (SONFH) is a refractory orthopedic disease.. While N6-methyladenosine (m6A) modification is implicated in bone metabolism, its specific role and mechanism in SONFH pathogenesis require further elucidation.. Methods: Bioinformatics analysis identified key m6A-related genes. Confocal:Article Title: DEAD-box RNA helicase 21 interacts with the nucleocapsid protein and inhibits porcine deltacoronavirus infection through upregulation of interferon responses. Article Snippet: The cells were then incubated with primary antibodies for 1 h, followed by washing with PBS and incubation with Alexa Fluor 488- and 594-conjugated secondary antibodies (Thermo Fisher Scientific) for 1 h at 37°C in the dark. .. Afterward, the cells were stained with Microscopy:Article Title: DEAD-box RNA helicase 21 interacts with the nucleocapsid protein and inhibits porcine deltacoronavirus infection through upregulation of interferon responses. Article Snippet: The cells were then incubated with primary antibodies for 1 h, followed by washing with PBS and incubation with Alexa Fluor 488- and 594-conjugated secondary antibodies (Thermo Fisher Scientific) for 1 h at 37°C in the dark. .. Afterward, the cells were stained with |
